InTroDuCTIon
Tigecycline is an important advance in treatment for a range of infections where mixed and/or resistant organisms play a role. It is able to bypass standard mechanisms of tetracycline resistance, and hence has a very broad spectrum that includes virtually all Grampositive bacteria, most Gram-negative bacteria including anaerobes, and many strains harbouring resistance to other antimicrobial classes. Tigecycline was launched in Australia in mid-2006, at a time when tetracycline resistance was known to be very common amongst almost all important human pathogens. At the time of its launch, we investigated its activity against a full range of pathogens isolated from hospitalised patients with serious infections.
MATerIAls AnD MeTHoDs
Bacterial isolates: Non-duplicate clinically significant patient isolates were submitted from five medical centres from five states of Australia. Species identification of all isolates was confirmed in a central laboratory (Women's and Children's Hospital, Adelaide, Australia) using reference methodologies.
Susceptibility tests: Isolates were tested against tigecycline using validated broth microdilution MIC panels with cation-adjusted Mueller-Hinton broth (TREK Diagnostic Systems; East Grinstead, UK). Testing and incubation were performed using the manufacturer's recommendations and/or reference Clinical and Laboratory Standards Institute (CLSI) methods (2006) . MIC tests were performed in cation-adjusted Mueller-Hinton broth (with the addition of 2-5% lysed horse blood for testing of streptococci). Quality control strains utilized included Escherichia coli ATCC 25922 and 35218, Pseudomonas aeruginosa ATCC 27853, S. aureus ATCC 29213 and S. pneumoniae ATCC 49619; all MIC results were within CLSI specified ranges. Analysis: MIC interpretation was performed using the manufacturer's recommendations and/or reference CLSI interpretative criteria (2008) . Tigecycline MIC results were interpreted using the US-FDA package insert (2005) in the absence of CLSI breakpoints. M100-S18, Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Wayne, PA: CLSI.
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• Resistance to tigecycline was not detected amongst Enterobacteriaceae or Moraxella catarrhalis. Other major resistances such as vancomycin resistance in enterococci, or carbapenemases, were uncommon in the monitored year. The rare strains collected with these resistances were susceptible to tigecycline.
